While evidence showing high vaccine effectiveness against severe COVID-19 among children and adolescents has been well documented, the shot’s effectiveness against MIS-C has been less explored, the report said.
The study involved 283 inpatients aged 12 to 18 across 24 U.S. pediatric hospitals from July to Dec. 9, 2021 — a period in which delta which was the dominant circulating strain and before children younger than 12 were eligible for the vaccine. A total of 102 of the patients had MIS-C, and a control group of 181 patients either tested negative for COVID-19 or did not have symptoms.
Most patients with MIS-C, 95 percent, were unvaccinated, the findings showed. Additionally, no fully vaccinated patient with MIS-C needed respiratory or cardiovascular life support, compared to 39 percent of unvaccinated MIS-C patients who did.
“Receipt of two doses of the Pfizer-BioNTech vaccine is associated with a high level of protection against MIS-C in persons aged 12-18, highlighting the importance of vaccination among all eligible children,” researchers said.
Pfizer’s vaccine is the only one authorized for use among people under the age of 18. Children 5 and older are eligible for primary vaccination, and boosters are recommended for those 12 and older.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
